However, given the very low rate of response in this small study population it is reasonable to include that short-term exposure to pexidartinib did not enhance response to paclitaxel in patients with high-risk early-stage HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.